AbbVie Inc (ABBV)
185.15
+2.98
(+1.64%)
USD |
NYSE |
Jul 26, 16:00
185.01
-0.14
(-0.08%)
After-Hours: 20:00
AbbVie Revenue (TTM): 54.40B for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 54.40B |
December 31, 2023 | 54.32B |
September 30, 2023 | 55.14B |
June 30, 2023 | 56.02B |
March 31, 2023 | 56.74B |
December 31, 2022 | 58.05B |
September 30, 2022 | 57.82B |
June 30, 2022 | 57.35B |
March 31, 2022 | 56.72B |
December 31, 2021 | 56.20B |
September 30, 2021 | 55.17B |
June 30, 2021 | 53.73B |
March 31, 2021 | 50.20B |
December 31, 2020 | 45.80B |
September 30, 2020 | 40.65B |
June 30, 2020 | 36.23B |
March 31, 2020 | 34.06B |
December 31, 2019 | 33.27B |
September 30, 2019 | 32.87B |
June 30, 2019 | 32.62B |
March 31, 2019 | 32.65B |
December 31, 2018 | 32.75B |
September 30, 2018 | 32.19B |
June 30, 2018 | 30.95B |
March 31, 2018 | 29.61B |
Date | Value |
---|---|
December 31, 2017 | 28.22B |
September 30, 2017 | 27.27B |
June 30, 2017 | 26.71B |
March 31, 2017 | 26.22B |
December 31, 2016 | 25.64B |
September 30, 2016 | 25.24B |
June 30, 2016 | 24.75B |
March 31, 2016 | 23.78B |
December 31, 2015 | 22.86B |
September 30, 2015 | 21.91B |
June 30, 2015 | 20.99B |
March 31, 2015 | 20.44B |
December 31, 2014 | 19.96B |
September 30, 2014 | 19.62B |
June 30, 2014 | 19.26B |
March 31, 2014 | 19.02B |
December 31, 2013 | 18.79B |
September 30, 2013 | 18.88B |
June 30, 2013 | 18.74B |
March 31, 2013 | 18.54B |
December 31, 2012 | 18.38B |
September 30, 2012 | 18.04B |
June 30, 2012 | 17.94B |
March 31, 2012 | 17.72B |
December 31, 2011 | 17.44B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
32.87B
Minimum
Sep 2019
58.05B
Maximum
Dec 2022
49.72B
Average
54.40B
Median
Mar 2024
Revenue (TTM) Benchmarks
Amgen Inc | 29.53B |
Gilead Sciences Inc | 27.45B |
Johnson & Johnson | 86.58B |
Eli Lilly and Co | 35.93B |
Merck & Co Inc | 61.40B |